Trials / Completed
CompletedNCT00165854
Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (planned)
- Sponsor
- Eisai Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7070 |
Timeline
- Start date
- 2003-03-01
- First posted
- 2005-09-14
- Last updated
- 2014-06-27
Locations
4 sites across 3 countries: France, Germany, Netherlands
Source: ClinicalTrials.gov record NCT00165854. Inclusion in this directory is not an endorsement.